Volume 10, Number 8, August 2004

Antimicrobial Drug Use and Methicillin-resistant Staphylococcus aureus, Aberdeen, 1996–2000

Dominique L. Monnet,* Fiona M. MacKenzie,† José María López-Lozano,‡ Arielle Beyaert,§ Máximo Camacho,§ Rachel Wilson,† David Stuart,† and Ian M. Gould†
*Statens Serum Institut, Copenhagen, Denmark; †Aberdeen Royal Infirmary, Aberdeen, Scotland; ‡Hospital Vega Baja, Orihuela (Alicante), Spain; and §University of Murcia, Murcia, Spain

Figure 2. Examples of graphic exploration of the relationship between the monthly % methicillin-resistant Staphylococcus aureus (%MRSA) and the monthly use of individual classes of antimicrobials, Aberdeen Royal Infirmary, January 1996–December 2000 (THICK LINE, %MRSA; THIN LINE, Antimicrobial use, 5-month moving average, right Y-axis); A) penicillins with β-lactamase inhibitors, B) macrolides, C) third-generation cephalosporins, D) fluoroquinolones, E) tetracyclines, and F) aminoglycosides.

EID Home | Top of Page | Ahead-of-Print | Past Issues | Suggested Citation | EID Search | Contact Us | Accessibility | Privacy Policy Notice | CDC Home | CDC Search | Health Topics A-Z

This page last reviewed July 22, 2004

Emerging Infectious Diseases Journal
National Center for Infectious Diseases
Centers for Disease Control and Prevention